Geneva Capital Management LLC Increases Stake in Certara, Inc. (NASDAQ:CERT)

Geneva Capital Management LLC boosted its stake in shares of Certara, Inc. (NASDAQ:CERT) by 29.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,824,850 shares of the company’s stock after purchasing an additional 860,763 shares during the period. Certara makes up about 1.3% of Geneva Capital Management LLC’s portfolio, making the stock its 29th biggest position. Geneva Capital Management LLC owned approximately 2.39% of Certara worth $67,279,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Rathbones Group PLC purchased a new position in Certara during the 3rd quarter worth approximately $11,007,000. Massachusetts Financial Services Co. MA grew its position in Certara by 33.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,110,074 shares of the company’s stock worth $30,680,000 after purchasing an additional 530,695 shares during the period. Kayne Anderson Rudnick Investment Management LLC raised its stake in shares of Certara by 48.8% during the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 727,240 shares of the company’s stock valued at $10,574,000 after buying an additional 238,603 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in shares of Certara by 45.5% in the 3rd quarter. TimesSquare Capital Management LLC now owns 519,075 shares of the company’s stock valued at $7,547,000 after buying an additional 162,255 shares during the period. Finally, Bamco Inc. NY boosted its stake in shares of Certara by 15.1% in the third quarter. Bamco Inc. NY now owns 1,069,103 shares of the company’s stock worth $15,545,000 after buying an additional 140,000 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Analyst Ratings Changes

CERT has been the subject of a number of analyst reports. UBS Group boosted their price target on Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, March 1st. SVB Leerink began coverage on shares of Certara in a report on Monday, February 26th. They set a “market perform” rating and a $19.00 price target on the stock. Jefferies Financial Group upped their price objective on shares of Certara from $14.00 to $15.50 and gave the stock a “hold” rating in a research report on Friday, March 1st. JMP Securities assumed coverage on Certara in a research report on Thursday, April 4th. They set a “market perform” rating on the stock. Finally, Leerink Partnrs reaffirmed a “market perform” rating on shares of Certara in a report on Monday, February 26th. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Certara currently has an average rating of “Hold” and a consensus target price of $20.06.

Certara Price Performance

CERT traded up $0.71 on Thursday, hitting $17.06. 555,141 shares of the company’s stock were exchanged, compared to its average volume of 537,756. The firm has a 50-day moving average price of $17.71 and a 200-day moving average price of $16.44. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -46.71, a P/E/G ratio of 1.81 and a beta of 1.61. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.28. Certara, Inc. has a fifty-two week low of $11.81 and a fifty-two week high of $22.65.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). The firm had revenue of $88.01 million for the quarter, compared to analyst estimates of $86.80 million. Certara had a positive return on equity of 4.33% and a negative net margin of 15.62%. As a group, equities analysts anticipate that Certara, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Certara

In other Certara news, insider Patrick F. Smith sold 14,427 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total transaction of $243,094.95. Following the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $844,033.35. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Patrick F. Smith sold 14,427 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $844,033.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Richard M. Traynor sold 6,000 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $18.00, for a total value of $108,000.00. Following the transaction, the senior vice president now directly owns 165,368 shares of the company’s stock, valued at $2,976,624. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,427 shares of company stock worth $405,095. 2.39% of the stock is currently owned by company insiders.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.